Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Technology appraisal guidance
Reference number: TA496
Published: 20 December 2017

History

Documents created during the development process.

Final appraisal determination: 1

Final appraisal determination: 1
Committee papers (PDF 10.84 MB)

Published:

16 November 2017
Final appraisal determination document (PDF 373 KB)

Published:

16 November 2017
Final appraisal determination document Equality Impact Assessment Form (PDF 221 KB)

Published:

16 November 2017
Public committee slides ACM1 - Clinical (PDF 766 KB)

Published:

16 November 2017
Public committee slides ACM1 - Cost (PDF 528 KB)

Published:

16 November 2017
Public committee slides ACM2 (PDF 687 KB)

Published:

16 November 2017
Public committee slides ACM3 (PDF 486 KB)

Published:

16 November 2017

Invitation to participate

Final scope (PDF 222 KB)

Published:

14 June 2017
Final matrix (PDF 258 KB)

Published:

14 June 2017
NICE's response to comments on the draft scope and provisional matrix (PDF 321 KB)

Published:

14 June 2017